• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

    5/7/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email
    • This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'
    • Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communities
    • Eleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coaches
    • American soccer icon Clint Dempsey will mentor the athletes throughout their journey

    ABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a once-in-a-lifetime opportunity to travel to Madrid where they will showcase their skills and learn from Real Madrid's legendary coaches. Abbott health experts will provide the athletes with the latest advancements in sports health and nutrition to help them gain a deeper understanding of their bodies and achieve peak performance. Upon returning from Madrid, the 'Abbott Dream Team' members will host health training sessions with Abbott at local soccer and youth organizations to inspire the next generation to embrace healthy habits.

    Abbott, in collaboration with Real Madrid, will host tryout events for the 'Abbott Dream Team' this summer in the following five cities: Chicago, Dallas, Los Angeles, Philadelphia and Washington, D.C. Up to 250 athletes, aged 18-19, will be allowed to participate at each location. All participants will engage in intensive soccer training sessions led by Real Madrid coaches and receive health and nutrition education from Abbott. Each attendee will leave with an Abbott health toolkit so they can share their learnings and encourage healthy behaviors within their communities.

    The 11 'Abbott Dream Team' players will be selected for outstanding soccer skills, values and determination on and off the pitch and sent to Madrid for an unforgettable experience. They will be trained by Real Madrid coaches inside the club's renowned training facilities at Ciudad Real Madrid and attend a match at the iconic Santiago Bernabéu Stadium. Beyond the pitch, the athletes will meet with Abbott sports nutrition experts and Real Madrid's medical team at the onsite "Abbott - Real Madrid Innovation Lab." They will discuss the latest advancements in athlete nutrition, gaining invaluable health insights to support their sports performance and well-being.

    One of the greatest American soccer players of all time, Clint Dempsey, is joining Abbott and Real Madrid to inspire the players throughout the process and share insight into the qualities essential to achieving their goals. Knowing firsthand what it takes to perform at the game's most elite level, Dempsey's advice on hard work, healthy habits and proper nutrition will provide a model for the athletes.

    "I benefited from world-class nutritional programming throughout my soccer career, and I know how crucial a strong health foundation is for reaching your full potential," Dempsey said. "That's why I believe Abbott's Dream Team program has the power to change the lives of young athletes by giving them the tools to thrive and uplift their communities."

    Joining the 'Abbott Dream Team'

    The 'Abbott Dream Team' tryouts will take place from June 17, 2025, to July 24, 2025, and spaces are limited to 250 people per event. Athletes must be between the ages of 18 to 19 at the time of the tryout and provide proof of age. Signup does not guarantee a place in the event and selected participants will be sent a confirmation notice following registration. Tryouts will take place at the following locations and dates:

    Tuesday, June 17: Dallas, TX

    • ULETE Soccer Center, 2308 Dean Way, Southlake, TX 76092

    Wednesday, June 25: Philadelphia, PA

    • Vidas Athletic Complex at Drexel University, 4300 Powelton Ave, Philadelphia, PA 19104

    Thursday, July 10: Washington, D.C.

    • University of Maryland, 90 Stadium Dr, College Park, MD 20742

    Thursday, July 17: Chicago, IL

    • Lake View High School, 4015 N Ashland Ave, Chicago, IL 60613

    Thursday, July 24: Los Angeles, CA

    • Jesse Owens Stadium at Cal State LA, 22 Circle Dr, Los Angeles, CA 90032

    Regardless of whether they are selected to join the 'Abbott Dream Team,' every tryout participant will receive soccer training from Real Madrid coaches, nutrition education from Abbott and will be enrolled in the Abbott Football Club (Abbott FC), a community of soccer fans who will have access to Abbott nutrition education resources and giveaways featuring Real Madrid merchandise.

    Interested athletes can visit www.AbbottDreamTeam.com for more information about signing up for the tryouts and program terms.

    Fueling the Next Generation With Good Health

    The 'Abbott Dream Team' will not only train with one of the world's top clubs but also learn about the importance of proper nutrition, physical activity and healthy habits from Abbott experts. The players will bring this knowledge home to promote the benefits of living a healthy lifestyle within their local communities by working with Abbott to create health training events at local soccer and youth organizations.

    The 'Abbott Dream Team' program is part of Abbott's and Real Madrid's ongoing 'Beat Malnutrition' campaign. Abbott, the Health Sciences and Nutrition Partner of the Real Madrid Football Club, provides nutrition education and malnutrition screening to children in 12 countries (Brazil, Colombia, Guatemala, India, Israel, Kenya, Mexico, Peru, Philippines, Tanzania, United Kingdom and United States). Since 2022, the partnership has delivered more than 67,000 hours of health and nutrition education and screened over 6,800 children for malnutrition risk. These efforts contribute to Abbott's goal of transforming care for malnutrition and improving the lives of 3 billion people per year by decade's end.

    "Our work with Real Madrid is rooted in empowering future generations through nutrition and sport," said Ann Smith, co-lead of the Abbott Center for Malnutrition Solutions. "Proper nutrition is the cornerstone of a full and healthy life, and we are thrilled to help exceptional young people fulfill their dreams while providing them with the tools to help their communities thrive."

    About Abbott

    Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

    Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

    About Real Madrid C.F.

    Real Madrid C.F. is a sport entity with 123 years of history. It is the club with the most European Cups of both football (15) and basketball (11) and was awarded by FIFA as the Best Club of the twentieth century. Real Madrid has millions of fans in all corners of the world, with more than 620 million followers on social media, being the strongest football brand in the world according to Brand Finance for the third year in a row and also the highest earning football club in the world in the 23-24 season (Football Money League by Deloitte). More information about Real Madrid C.F. is available at www.realmadrid.com, the most visited football club website for the seventh consecutive year.

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

     

    Abbott Logo

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/abbott-and-real-madrid-kick-off-search-to-empower-young-soccer-talent-302448407.html

    SOURCE Abbott

    Get the next $ABT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    5/30/2023$112.00Overweight → Equal-Weight
    Morgan Stanley
    4/20/2023$125.00 → $127.00Overweight
    Barclays
    4/20/2023$107.00 → $103.00Underperform
    Wolfe Research
    More analyst ratings

    $ABT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/13/24 4:55:58 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/9/23 10:54:50 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/9/22 3:15:56 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

      For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

      10/24/23 3:52:17 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

      Leadership appointment strengthens strategic and development capabilities FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin Collaboration Agreement with Abbott (NYSE:ABT) validates the need for new anticoagulation options Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin. "In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024," sa

      5/8/25 8:00:00 AM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

      This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

      5/7/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races

      The test, run on Abbott's portable i-STAT® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concussion, producing lab-quality results in 15 minutesThe test will be used by healthcare professionals in the medical facilities at all MotoAmerica races in 2025ABBOTT PARK, Ill., and IRVINE, Calif., May 1, 2025 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare company, and MotoAmerica, the premier motorcycle road racing series in North America, announced today that MotoAmerica is the first professional sports organization worldwide to use Abbott's groundbreaking blood test to help assess suspe

      5/1/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Financials

    Live finance-specific insights

    See more
    • Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

      First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increaseReported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increaseABBOTT PARK, Ill., April 16, 2025 /PRNewswire/ --  Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2025. First-quarter sales increased 4.0 percent on a reported basis, 6.9 pe

      4/16/25 7:30:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Hosts Conference Call for First-Quarter Earnings

      ABBOTT PARK, Ill., March 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medi

      3/26/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

      Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership appointments to strengthen development capabilities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin. "2024 for Cadrenal was a year of

      3/13/25 4:05:00 PM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Leadership Updates

    Live Leadership Updates

    See more
    • Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

      This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

      5/7/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

      Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

      3/4/25 11:38:00 AM ET
      $ABT
      $TFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Abbott Labs with a new price target

      Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00

      10/8/24 7:11:39 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Abbott Labs with a new price target

      Piper Sandler initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $131.00

      9/19/24 7:31:59 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Labs downgraded by Edward Jones

      Edward Jones downgraded Abbott Labs from Buy to Hold

      7/30/24 6:16:11 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blount Sally E. sold $337,116 worth of Common shares without par value (2,600 units at $129.66), decreasing direct ownership by 7% to 34,058 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      5/2/25 5:04:05 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Stratton John G was granted 1,635 units of Common shares without par value, increasing direct ownership by 9% to 19,033 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:30:29 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Starks Daniel J was granted 1,635 units of Common shares without par value, increasing direct ownership by 0.02% to 6,728,817 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:22:08 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    SEC Filings

    See more
    • Abbott Laboratories filed SEC Form 8-K: Leadership Update

      8-K - ABBOTT LABORATORIES (0000001800) (Filer)

      5/1/25 4:01:21 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Abbott Laboratories

      10-Q - ABBOTT LABORATORIES (0000001800) (Filer)

      4/30/25 4:14:32 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Laboratories filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ABBOTT LABORATORIES (0000001800) (Filer)

      4/28/25 4:10:13 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care